Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2019-03-26 Regulatory Filings
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Genmab Announces Submission of Supplemental Biologics License Application to FDA for Daratumumab in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma
Regulatory Filings Classification · 95% confidence The document is a corporate announcement from Genmab regarding the submission of a supplemental Biologics License Application (sBLA) to the FDA. It provides details on the clinical study (CASSIOPEIA) and the regulatory milestone. While it contains detailed information, it is structured as a standard corporate press release/announcement. According to the 'Menu vs Meal' rule, this is a regulatory announcement of a filing rather than the filing itself. It fits best under the 'Regulatory Filings' (RNS) category as it is a general corporate announcement regarding regulatory progress.
2019-03-26 English
Regulatory Filings 2019
Regulatory Filings Classification · 100% confidence The document is titled "Genmab Announces European Regulatory Submission for Daratumumab..." and explicitly states that a "Type II variation application submitted to the EMA" has occurred. This is a specific announcement regarding a regulatory action concerning a drug application, not a comprehensive financial report (like 10-K or IR) or a general regulatory filing (RNS). Since the document details a specific regulatory submission event, it fits best under the general category of regulatory or legal updates. Given the options, this is a specific announcement about a regulatory filing/submission. While it is not a standard SEC form, it is a formal announcement of a regulatory step. It is not a Call Transcript (CT), Earnings Release (ER), or a standard financial report (10-K, IR). It is an announcement of a regulatory action, which often falls under the broader 'Regulatory Filings' (RNS) if a more specific code isn't available. However, since it is a formal announcement about a specific regulatory submission (Type II variation application to EMA), and there isn't a code for 'Drug Regulatory Submission', RNS serves as the most appropriate general regulatory announcement category, as it is a formal communication to the market about a regulatory event.
2019-03-22 English
Genmab Announces European Regulatory Submission for Daratumumab in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma
Regulatory Filings Classification · 95% confidence The document is a 'Company Announcement' from Genmab regarding a regulatory submission to the EMA. It is relatively short, provides a summary of the news, and explicitly includes an 'Attachment' link at the bottom for the full details of the submission. According to the 'Menu vs Meal' rule, documents that announce the publication of a report or provide an attachment link are classified as Report Publication Announcements (RPA).
2019-03-22 English
Regulatory Filings 2019
Regulatory Filings
2019-02-28 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change Classification · 100% confidence The document is a formal company announcement from Genmab regarding an increase in share capital resulting from the exercise of employee warrants. It details the number of shares issued, the subscription prices, the impact on total share capital, and the regulatory compliance with the Danish Capital Markets Act. This fits the definition of a 'Share Issue/Capital Change' (SHA) as it describes a specific event involving the issuance of new shares and a change in the company's capital structure.
2019-02-26 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change Classification · 100% confidence The document is a company announcement detailing an increase in share capital resulting from the exercise of employee warrants. It specifies the number of shares issued, the subscription prices, and the resulting total share capital. This falls directly under the definition of a 'Share Issue/Capital Change' (SHA) filing, as it describes a change in the company's capital structure due to new share issuance.
2019-02-26 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.